PDCD1 and cancer: In cancer immunotherapy, CRISPR-Cas9-mediated genome editing is usually applied to knockout the genes that encode inhibitory receptor proteins of tumor or T cells, such as PD-1, PD-L1, and CTLA-4184-186.